Recurrent Melanoma Recruiting Phase 1 / 2 Trials for Navitoclax (DB12340)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01989585Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTreatment